Analysts’ Weekly Ratings Updates for Exagen (XGN)

Exagen (NASDAQ: XGN) recently received a number of ratings updates from brokerages and research firms:

• 3/14/2026 – Exagen was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/11/2026 – Exagen had its price target lowered by Canaccord Genuity Group Inc. from $15.00 to $10.00. They now have a “buy” rating on the stock.
• 3/11/2026 – Exagen had its price target lowered by Craig Hallum from $12.00 to $10.00. They now have a “buy” rating on the stock.
• 3/11/2026 – Exagen had its price target lowered by KeyCorp from $15.00 to $10.00. They now have an “overweight” rating on the stock.
• 3/10/2026 – Exagen had its “outperform” rating reaffirmed by William Blair.
• 3/10/2026 – Exagen had its price target lowered by BTIG Research from $10.00 to $9.00. They now have a “buy” rating on the stock.
• 2/24/2026 – Exagen had its price target lowered by TD Cowen from $13.00 to $10.00. They now have a “buy” rating on the stock.
• 2/17/2026 – Exagen had its price target lowered by BTIG Research from $15.00 to $10.00. They now have a “buy” rating on the stock.
• 1/30/2026 – Exagen had its “buy” rating reaffirmed by B. Riley Financial, Inc.. They now have a $8.00 price target on the stock, down from $18.00.

Insider Buying and Selling at Exagen

In other news, CEO John Aballi sold 15,698 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $3.62, for a total transaction of $56,826.76. Following the transaction, the chief executive officer directly owned 687,299 shares of the company’s stock, valued at $2,488,022.38. This represents a 2.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 12.60% of the company’s stock.

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.